Discover the future of CD123 Targeting Therapies with our Global Market Trends & Outlook 2025 report. Examine clinical trials, technology innovations, and market dynamics as this field expands from ...

The growing prevalence of chronic diseases is a major factor driving revenue growth in the natural killer (NK) cell ...

NKGen Biotech, Inc. (OTC: NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization ...

Even a little movement goes a long way. As Dr. George explains, just 75 minutes of activity a week, that’s about 11 minutes a ...

Mesenchymal stem cell therapy lessens disability and brain lesions in MS patients, according to a review of published studies ...

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class ...

In an interview with Moneycontrol on July 14, Glenn Saldanha, Chairman and Managing Director of Glenmark, discussed the ...

Lactate released by tumor cells has been shown to inhibit antitumor NK cell responses. Here the authors show a mechanism for this effect in which lactate drives lysine lactylation of NK cells.

An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year ...

An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year worldwide ( ) with these numbers expected to grow. The American Cancer Society ...

Orca-T shows significant promise in reducing chronic graft-vs-host disease and improving survival rates in allogeneic transplant patients with hematologic malignancies.